BioRem Inc.
BRM.V · TSXV
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.44 | 0.18 | 0.05 | -0.75 |
| FCF Yield | 6.89% | -0.40% | 9.11% | 11.46% |
| EV / EBITDA | 9.64 | 5.10 | 4.88 | 12.52 |
| Quality | ||||
| ROIC | 22.47% | 21.94% | 19.29% | 17.30% |
| Gross Margin | 26.87% | 27.90% | 30.36% | 25.48% |
| Cash Conversion Ratio | 1.21 | 0.22 | 0.90 | 2.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.04% | 0.93% | 5.79% | 5.83% |
| Free Cash Flow Growth | 5,372.35% | -105.06% | -66.50% | 23.82% |
| Safety | ||||
| Net Debt / EBITDA | -0.34 | 0.55 | 0.32 | 0.45 |
| Interest Coverage | 22.22 | 11.20 | 10.27 | 57.73 |
| Efficiency | ||||
| Inventory Turnover | 9.42 | 20.13 | 22.64 | 20.23 |
| Cash Conversion Cycle | 130.13 | 113.40 | 85.38 | 67.78 |